Tempus AI, Inc Stock

Equities

TEM

US88023B1035

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-15 EDT Pre-market 09:09:58
36.6 USD -7.92% Intraday chart for Tempus AI, Inc 38.35 +4.78%
Sales 2024 * 690M 946M Sales 2025 * 922M 1.26B Capitalization 6.03B 8.27B
Net income 2024 * -747M -1.02B Net income 2025 * -231M -316M EV / Sales 2024 * 8.6 x
Net cash position 2024 * 96.84M 133M Net cash position 2025 * 77.19M 106M EV / Sales 2025 * 6.46 x
P/E ratio 2024 *
-7.95 x
P/E ratio 2025 *
-26.6 x
Employees 1,500
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.78%
1 week+10.24%
Current month+4.57%
1 month-9.07%
More quotes
1 week
34.45
Extreme 34.45
41.78
1 month
22.89
Extreme 22.89
43.00
Current year
22.89
Extreme 22.89
43.88
1 year
22.89
Extreme 22.89
43.88
3 years
22.89
Extreme 22.89
43.88
5 years
22.89
Extreme 22.89
43.88
10 years
22.89
Extreme 22.89
43.88
More quotes
Date Price Change Volume
24-07-15 36.6 -7.95% 1,039,671
24-07-12 39.76 +6.03% 1,633,543
24-07-11 37.5 +7.14% 982,889
24-07-10 35 +1.45% 1,079,337
24-07-09 34.5 +3.92% 2,065,089

Delayed Quote Nasdaq, July 15, 2024 at 04:00 pm

More quotes
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
36.6 USD
Average target price
46 USD
Spread / Average Target
+25.68%
Consensus